Table 1.
Baseline characteristics according to randomisation for duration of dual antiplatelet therapy (DAPT) after implantation of drug eluting stent in randomised controlled trials according to diabetes status. Figures are percentages (numbers) of patients unless specified otherwise
| Characteristic | Diabetes (n=3681) | No diabetes (n=7708) | |||||
|---|---|---|---|---|---|---|---|
| Long DAPT (n=1853) | Short DAPT (n=1828) | P value | Long DAPT (n=3848) | Short DAPT (n=3860) | P value | ||
| Mean (SD) age (years) | 63.7 (10.0) | 63.6 (9.9) | 0.60 | 62.8 (11.1) | 62.8 (10.8) | 0.73 | |
| Men | 64.0 (1186/1853) | 65.8 (1202/1828) | 0.27 | 72.0 (2770/3848) | 72.2 (2787/3860) | 0.83 | |
| Hypertension | 87.4 (1618/1852) | 87.0 (1591/1828) | 0.76 | 75.1 (2889/3846) | 74.5 (2873/3856) | 0.54 | |
| Hypercholesterolaemia | 72.3 (1326/1834) | 71.9 (1302/1810) | 0.81 | 60.7 (2308/3803) | 60.1 (2296/3821) | 0.59 | |
| Smoking | 17.6 (274/1558) | 19.5 (301/1543) | 0.17 | 23.6 (799/3381) | 24.0 (816/3403) | 0.74 | |
| Previous myocardial infarction | 22.6 (371/1638) | 25.2 (416/1652) | 0.09 | 21.2 (742/3505) | 20.2 (706/3501) | 0.30 | |
| Previous PCI | 19.5 (321/1646) | 21.4 (354/1658) | 0.19 | 15.7 (550/3511) | 16.6 (585/3516) | 0.27 | |
| Previous CABG | 7.7 (126/1645) | 7.3 (121/1657) | 0.70 | 5.6 (196/3507) | 5.4 (190/3518) | 0.73 | |
| Previous stroke | 4.4 (54/1230) | 6.2 (78/1257) | 0.05 | 3.3 (81/2457) | 3.1 (78/2482) | 0.76 | |
| Creatinine >106.08 μmol/L | 10.9 (79/725) | 8.2 (59/720) | 0.08 | 7.4 (133/1804) | 6.9 (125/1812) | 0.58 | |
| Clinical presentation: | |||||||
| Stable angina pectoris | 62.5 (1159/1853) | 59.8 (1094/1828) | 0.09 | 56.6 (2178/3847) | 57.7 (2227/3860) | 0.34 | |
| Acute coronary syndrome | 37.5 (694/1853) | 40.2 (734/1828) | 43.4 (1669/3847) | 42.3 (1633/3860) | |||
| STEMI | 3.3 (61/1853) | 3.0 (55/1828) | — | 6.4 (247/3847) | 6.9 (265/3860) | — | |
| NSTEMI | 7.4 (137/1853) | 7.2 (131/1828) | — | 9.0 (348/3847) | 8.5 (328/3860) | — | |
| Unstable angina | 26.8 (496/1853) | 30.0 (548/1828) | — | 27.9 (1074/3847) | 26.9 (1040/3860) | — | |
| Discharge drugs: | |||||||
| Aspirin | 99.9 (1292/1293) | 99.9 (1277/1278) | 0.99 | 99.5 (2693/2706) | 99.8 (2694/2699) | 0.06 | |
| Clopidogrel | 99.8 (1290/1293) | 99.6 (1273/1278) | 0.47 | 99.7 (2699/2706) | 99.6 (2688/2699) | 0.49 | |
| β blockers | 71.5 (765/1070) | 70.8 (759/1072) | 0.72 | 70.0 (1555/2222) | 68.4 (1527/2232) | 0.26 | |
| ACEI/ARB | 60.3 (645/1070) | 62.6 (671/1072) | 0.27 | 56.9 (1265/2222) | 57.1 (1275/2232) | 0.90 | |
| Statins | 86.5 (926/1070) | 87.7 (940/1072) | 0.43 | 86.8 (1928/2222) | 88.1 (1966/2232) | 0.19 | |
| Mean (SD) diseased vessels/patient | 1.53 (0.9) | 1.54 (0.9) | 0.79 | 1.48 (0.8) | 1.49 (0.8) | 0.81 | |
| Mean (SD) No of treated vessels/patient | 1.22 (0.5) | 1.25 (0.5) | 0.15 | 1.21 (0.4) | 1.20 (0.4) | 0.41 | |
| Mean (SD) No of stents/patient | 1.58 (0.9) | 1.60 (0.9) | 0.64 | 1.51 (0.8) | 1.48 (0.8) | 0.31 | |
| Mean (SD) No of lesions stented/patient | 1.33 (0.6) | 1.34 (0.6) | 0.83 | 1.26 (0.5) | 1.26 (0.5) | 0.53 | |
| Mean (SD) total stent length/patient (mm) | 39.0 (26.1) | 39.3 (26.7) | 0.85 | 34.6 (22.9) | 33.9 (23.1) | 0.35 | |
| Mean (SD) smallest stent implanted (mm) | 3.0 (0.5) | 3.0 (0.4) | 0.35 | 3.1 (0.8) | 3.1 (0.5) | 0.78 | |
| Type of drug eluting stent: | |||||||
| PES | 4.1 (75/1844) | 4.2 (76/1820) | <0.001 | 4.8 (182/3831) | 4.8 (183/3840) | <0.001 | |
| SES | 4.3 (80/1844) | 3.7 (68/1820) | 11.1 (425/3831) | 2.5 (96/3840) | |||
| EES | 39.4 (727/1844) | 34.7 (631/1820) | 35.4 (1357/3831) | 30.9 (1185/3840) | |||
| ZES | 47.5 (875/1844) | 52.9 (962/1820) | 44.1 (1689/3831) | 57.0 (2190/3840) | |||
| BES | 4.0 (74/1844) | 3.8 (70/1820) | 4.0 (154/3831) | 4.2 (160/3840) | |||
| Mixed | 0.5 (9/1844) | 0.4 (8/1820) | 0.5 (19/3831) | 0.3 (13/3840) | |||
| Other | 0.2 (4/1844) | 0.3 (5/1820) | 0.1 (5/3831) | 0.3 (13/3840) | |||
| Stented coronary artery: | |||||||
| Left main | 2.3 (23/998) | 2.7 (27/1002) | 0.58 | 2.3 (54/2369) | 2.2 (52/2372) | 0.84 | |
| LAD | 62.5 (726/1161) | 65.5 (763/1165) | 0.14 | 62.8 (1657/2639) | 62.3 (1656/2659) | 0.70 | |
| LCx | 35.1 (381/1087) | 33.0 (358/1085) | 0.31 | 31.2 (778/2497) | 30.7 (758/2472) | 0.71 | |
| RCA | 39.7 (428/1078) | 39.8 (434/1091) | 0.97 | 34.5 (862/2497) | 30.6 (868/2508) | 0.95 | |
| Bifurcation | 18.4 (115/624) | 18.8 (115/612) | 0.87 | 16.0 (225/1410) | 14.3 (203/1424) | 0.21 | |
| Chronic total occlusion | 2.0 (22/1084) | 2.7 (29/1083) | 0.32 | 2.3 (51/2240) | 2.4 (55/2247) | 0.71 | |
BES=biolimus eluting stent; CABG=coronary artery bypass graft; EES=everolimus eluting stent; GFR=glomerular filtration rate; LAD=left anterior descending artery; NSTEMI=non-ST elevation myocardial infarction; PCI=percutaneous coronary intervention; PES=paclitaxel eluting stent; SES=sirolimus eluting stent; STEMI= ST elevation myocardial infarction; SVG=saphenous vein graft; ZES=zotarolimus eluting stent.